

Patents visualization in Cortellis

Cortellis Competitive Intelligence

This guide explains how to visualize patenting volumes on a specific indication or mechanism of action in recent years with Cortellis Competitive Intelligence in just a few clicks.

There are more than 5 million patent families available in Cortellis and they've all been through the same process of indexing, enhancement and curation expertly done by the editorial team. Patents are one of the most important sources of information in Cortellis as they include more than 100 authorities worldwide. How can you manage and analyze patents with such a high volume of data? How can you identify trends? Cortellis Competitive Intelligence offers different options to visualize patents in exportable charts. These allow you to analyze patenting volumes and identify top patent holders and related indications/mechanism of action with just a few clicks.

Example: Identify top patent holders and visualize B-cell lymphoma patents that have been published in the last 10 years.

- 1. Go to the 'Analysis' portlet in the Competitive Intelligence tile and select the 'Intellectual property landscape'
- 2. Click 'Indication' to access Cortellis hierarchical tree for this category.

Competitive Intelligence	e						ψ –
Drugs Literature Patents	•	Litera From 05/12/2	ture To 2021 13/12/2021		Active drugs coverage by highest status		Analysis Competitive landscape viewer Cortellis Analytics - Drug Attrition Rates Competitive intelligence matrix: Virtual merger Intellectual property landscape
Patent gazette	•	View	All 🗸		Preclinical Clinical Approved		Launch an interactive visualization of the
View All		314	Antimicrobials				Intellectual Property landscape around Indication Company Action

3. Look up and select 'B-cell lymphoma'.

ANALYZE - INDICATION		or Esc key
b-cell lymp		Look up
Select from those listed below Hierarchy Look-up List		
Hematological disease Uymphatic system disease Juphatic system tumor Juphatic sys		
B B-cell lymphoma Diffuse large B-cell lymphoma Primary mediastinal large B-cell lymphoma B High grade B-cell lymphoma D High grade B-cell lymphoma	When using hierarchical terms, sub terms are included automatically.	

© 2021 Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.



Competitive Intelligence			÷ –
Drugs Literature Patents Patent gazette View All Drugs Companies Patents Literature Broker research	Literature From To 05/12/2021 13/12/2021 View All 314 Antimicrobials 559 Cancer, Chemotherapy, Endocrine System 146 Cardiovascular System 202 Central Nervous System	Active drugs coverage by highest status • Discovery • Preclinical • Clinical • Approved	Analysis Competitive landscape viewer Cortellis Analytics - Drug Attrition Rates Competitive intelligence matrix Virtual merger Intellectual property landscape Launch an interactive visualization of the Intellectual Property landscape around Indication Company Action B-cell lymphoma Analyze

4. Click 'Analyze' to open a new tab.

5. Apply the 'Drug relationship' filter on the right to focus on patents protecting processes and products, for example. To include multiple values, hold the CTRL key when selecting.

Drug Relationship:	
Type to search in list	Q
General interest	
New use	
Process	
Process (Intermediate)	
Product	
Product (derivative)	
Tentative	



6. Move sliders at the top to narrow down the timeframe to the last 10 years or more. Bar chart displaying patenting volumes updates automatically allowing to identify top holders in this period of time. Names of top patent can be found on the right.



7. Table at the bottom of the page provides details on patent numbers, drug names and mechanism of actions to help you understand who your competitors are and what they're focusing on:

Family	Parent Company	Company	Company Relationship	Drug	Drug Relationship	Indication	Action	Class
CN-10235	Jiangsu Aosaikang	Jiangsu Aosaikang Pha	Patent Assignee/Owner	bendamusti	Product (derivative)	B-cell lymphoma	PARP modulator	Product derivative
CN-10469	Porton Pharma Solut	Porton Pharma Solutio	Patent Assignee/Owner	ibrutinib	Process (Intermed	B-cell lymphoma	Btk tyrosine kinase inhibitor,	Process
CN-10494	HEC Pharm	Guangdong HEC Phar	Patent Assignee/Owner	ibrutinib	Process (Intermed	B-cell lymphoma	Btk tyrosine kinase inhibitor	Process



8. Pie chart on the right displays the percentage of patents protecting different types of innovations of interest. Export options can be found at the top right of the screen as shown next:



To find out what patent content included in your subscription, contact your Clarivate account manager or <u>LS Product</u> <u>Support.</u>